CanBas Co., Ltd.
(株)キャンバス
2026/07/24 Updated
Market Cap:
$86.9M (¥14.2B)
Stock Price:
$4.41 (¥723)
Exchange Rate: 1 USD = ¥163.93
Stock Price Chart
2026/07/24 Updated0.00
PER (Price Earnings Ratio)
vs Industry Avg: -9.6
6.87
PBR (Price to Book Ratio)
vs Industry Avg: +5.6
0.00%
Dividend Yield
vs Industry Avg: -2.95%
Price Trend
2026/07/24 UpdatedShort-term
5-Day MA
+0.25%
Near-term
25-Day MA
+9.59%
Mid-term
75-Day MA
+10.01%
Long-term
200-Day MA
-7.43%
Price & Trading Details
2026/07/24 UpdatedPRICE
Previous Close
¥727
Open
¥718
High
¥727
Low
¥709
Close
¥723
TRADING
Volume
120,800
Average Volume
218,190
Turnover
¥87,338,400
Min. Purchase
¥72,300
Shareholder Composition
Updated 2026/07/013.3%
Insider Holdings
2.1%
Institutional
94.6%
Public Float
3
Institutional Holders
Insider Holdings
3.3%
Institutional
2.1%
Public Float
94.6%
Financial Performance
2026/07/26 UpdatedNo financial data available
Latest IR Information
Latest News (5 items)
Company Information
English Name
CanBas Co., Ltd.
Japanese Name
(株)キャンバス
Stock Code
4575.T (JPX)
Sector / Industry
Healthcare / Biotechnology
Website
https://www.canbas.co.jp
Employees
14
About
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Data provided by Yahoo Finance
